## **Special Issue**

# The Regulatory Roles of the Gut Microbiota in Multisystem Diseases

## Message from the Guest Editors

Biomedical science is currently witnessing a turning point-the so-called microbiota revolution. Accumulating evidence highlights the pivotal role of the microbiota in multisystem disease pathophysiology, leading to more awareness and ongoing research in this field. Clarifying this complex interaction can enhance our knowledge and potentially facilitate the development of increasingly precise, patient-targeted therapeutic strategies. The focus in research has shifted from analyzing bacterial populations to studying broader aspects of microbial elements. Of these, bacteriophages, particularly engineered ones, are proving significant, being promoted as preventive and therapeutic agents. This Special Issue aims to garner high-quality contributions that examine the importance of the microbiota in common and less common diseases, with particular emphasis on internal medicine. The improved survival rates of patients with inherited metabolic diseases, such as Fabry disease and phenylketonuria, pose new clinical challenges that require innovative pathophysiological insights and new treatment approaches.

## **Guest Editors**

Dr. Mario Caldarelli

- 1. Department of Translational Medicine and Surgery, Catholic University of Sacred Heart, 00168 Rome, Italy
- 2. Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy

#### Dr. Rossella Cianci

Department of Translational Medicine and Surgery, Catholic University, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy

### Deadline for manuscript submissions

31 January 2026



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/242907

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

